CLL patient samples
| CLL patient . | ZAP-70* . | CD38* . | ATM/TP53 function . | 17p−† . | 11q− . | Treatment history . |
|---|---|---|---|---|---|---|
| 1 | 72.1 | 57.7 | ND | +/− (11) | +/+ | FCR |
| 2 | 12.1 | 2.43 | N | +/+ | +/+ | NT |
| 3 | 4.26 | 1.49 | N | +/+ | +/+ | NT |
| 4 | 12.1 | 2.43 | N | +/+ | +/+ | NT |
| 5 | 8.5 | 0.1 | N | +/+ | +/+ | FCR |
| 6 | 77.4 | 2.9 | 3 | +/− (15) | +/+ | FCR |
| 7 | 4.36 | 2.22 | N | +/+ | +/+ | FCR |
| 8 | 17.8 | 57.7 | N/2 | +/+ | +/+ | CLB |
| 9 | 37.3 | 89.6 | 1 | +/− (88) | +/+ | Multiple |
| 10 | 43.7 | 53.1 | N | +/− (62) | +/+ | FCR |
| 11 | 26.1 | 57.7 | N | +/+ | +/+ | CLB, FCR |
| 12 | 66.8 | 84.2 | N | +/− (12) | +/+ | NT |
| 13 | 16.2 | 14.6 | N | +/− (23) | +/+ | Multiple |
| 14 | 3.3 | 0 | 1 | +/+ | +/+ | ND |
| 15 | 3.3 | 17.9 | 3 | ND | ND | NT |
| 16 | ND | 5.38 | 1 | ND | ND | NT |
| 17 | 19.1 | 0.3 | N | ND | ND | ND |
| 18 | 2.84 | 4.26 | N | +/+ | +/+ | FCR |
| 19 | 1.64 | 0.2 | N | +/+ | +/+ | RCVP/CHOP |
| 20 | 62 | 35.6 | ND | +/+ | +/+ | FCR |
| CLL patient . | ZAP-70* . | CD38* . | ATM/TP53 function . | 17p−† . | 11q− . | Treatment history . |
|---|---|---|---|---|---|---|
| 1 | 72.1 | 57.7 | ND | +/− (11) | +/+ | FCR |
| 2 | 12.1 | 2.43 | N | +/+ | +/+ | NT |
| 3 | 4.26 | 1.49 | N | +/+ | +/+ | NT |
| 4 | 12.1 | 2.43 | N | +/+ | +/+ | NT |
| 5 | 8.5 | 0.1 | N | +/+ | +/+ | FCR |
| 6 | 77.4 | 2.9 | 3 | +/− (15) | +/+ | FCR |
| 7 | 4.36 | 2.22 | N | +/+ | +/+ | FCR |
| 8 | 17.8 | 57.7 | N/2 | +/+ | +/+ | CLB |
| 9 | 37.3 | 89.6 | 1 | +/− (88) | +/+ | Multiple |
| 10 | 43.7 | 53.1 | N | +/− (62) | +/+ | FCR |
| 11 | 26.1 | 57.7 | N | +/+ | +/+ | CLB, FCR |
| 12 | 66.8 | 84.2 | N | +/− (12) | +/+ | NT |
| 13 | 16.2 | 14.6 | N | +/− (23) | +/+ | Multiple |
| 14 | 3.3 | 0 | 1 | +/+ | +/+ | ND |
| 15 | 3.3 | 17.9 | 3 | ND | ND | NT |
| 16 | ND | 5.38 | 1 | ND | ND | NT |
| 17 | 19.1 | 0.3 | N | ND | ND | ND |
| 18 | 2.84 | 4.26 | N | +/+ | +/+ | FCR |
| 19 | 1.64 | 0.2 | N | +/+ | +/+ | RCVP/CHOP |
| 20 | 62 | 35.6 | ND | +/+ | +/+ | FCR |
1, TP53 mutated; 2, ATM mutated; 3, evidence of low-level TP53 dysfunction; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CLB, chlorambucil; FCR, fludarabine, cyclophosphamide, and rituximab; N, normal ATM/TP53; ND, no data; NT, no previous treatment; RCVP, rituximab, cyclophosphamide, vincristine, and prednisolone.
Cutoffs for ZAP-70 and CD38 positivity were 10% and 7%, respectively.
Clone sizes for deletions of 17p are shown in parentheses.